Abstract
Acute kidney injury (AKI) is a growing global health problem with increased mortality and morbidity. Cisplatin is achemotherapy drug first introduced in 1978, and since then, it became one of the most widely used and successful anti-cancer medication. However, there are risks associated with cisplatin administration, such as nephrotoxicity. Mechanisms of nephrotoxicity include proximal tubular injury, DNA damage, apoptosis, inflammation, oxidative stress, and vascular injury. Although various protocols are being used in clinical practice in nephrotoxicity prevention due to cisplatin, there are no clear guidelines regarding this approach. Most recommendations include hydration and avoiding additional nephrotoxic drugs. To prevent nephrotoxicity, future perspectives could rely on natural products, such as flavonoids or saponins or pharmacological products, such as aprepitant, but data are scarce in this direction. Repetitive administration of cisplatin could cause subclinical kidney injury, which over time, leads to chronic kidney disease (CKD). Therefore, more studies are needed to determine possible ways to prevent nephrotoxicity and avoid the burden of CKD worldwide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sawhney S, Fraser SD (2017) Epidemiology of AKI: utilizing large databases to determine the burden of AKI. Adv Chronic Kidney Dis 24(4):194–204
Gómez-Ruiz S et al (2012) On the discovery, biological effects, and use of cisplatin and metallocenes in anticancer chemotherapy. Bioinorg Chem Appl 2012:140284
McSweeney KR et al (2021) Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers 13(7):1572
Sara A (2019) Aldossary, review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J 12(1):7–15
Hapani N, D’Cruz S, Dimri K (2022) POS-017 incidence of acute kidney injury in patients receiving cisplatin and carboplatin and to evaluate associated risk factors for acute kidney injury. Kidney Int Rep 7(2):S7–S8
Volarevic V et al (2019) Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 26(1):25
Sears SM, Siskind LJ (2021) Potential therapeutic targets for cisplatin-induced kidney injury: lessons from other models of AKI and fibrosis. J Am Soc Nephrol 32(7):1559–1567
Ozkok AEC (2014) Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int.
Crona DJ, FA, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI (2014) A Systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist.
Li S, He X, Ruan L, Ye T, Wen Y, Song Z, Hu S, Chen Y, Peng B, Li S (2021) Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: a systematic review and meta-analysis. Front Oncol.
Rachman A, Wafa S, Nugroho P, et al (2022) The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: an ambispective cohort study. BMC Cancer 22
Casanova AG, Hernández-Sánchez MT, López-Hernández FJ, et al (2020) Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity. Eur J Clin Pharmacol 76
Fang CY, LD, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ, Weng QJ (2021) Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin 42(12)
Harun U, RAU, Duygu K, Yasin B, Elif C, Jale S, Zekai H (2020) A novel effect of aprepitant: protection for cisplatin-induced nephrotoxicity and hepatotoxicity. Eur J Pharmacol 880
Cierra N, Sharp MAD, Judit M, Gabrielle BO, Levi JB, Leah JS (2018) Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am J Physiol 315(1)
Duan ZCG, Li J Chen X (2020) Cisplatin-induced renal toxicity in elderly people. Thera Adv Med Oncol 12
van der Vorst MJDL, Neefjes ECW, Toffoli EC et al. (2019) Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer 19
Acknowledgements
This work was supported by a Grant of “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania: “Prevention of cisplatin nephrotoxicity in cancer patients”, funding contract 6986/21.04.2020
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that there is no conflict of interest regarding the publication of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Volovat, S., Apetrii, M., Stefan, A. et al. Cisplatin and AKI: an ongoing battle with new perspectives—a narrative review. Int Urol Nephrol 55, 1205–1209 (2023). https://doi.org/10.1007/s11255-022-03418-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-022-03418-8